Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 4/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | EEF2K | O00418 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2055456 | 0.85 | ACLY (0.38) | ALDH1A1HSD17B10TDP1ACLYHTR6 | |
| SCHEMBL17331594 | 0.84 | ALDH1A1 (0.34) | ALDH1A1HSD17B10TDP1CA1CA9 | |
| SCHEMBL22447746 | 0.84 | FFAR4 (0.38) | ALDH1A1HSD17B10TDP1FEN1PTGS2 | |
| SCHEMBL30990667 | 0.84 | FFAR4 (0.38) | ALDH1A1HSD17B10TDP1FEN1PTGS2 | |
| SCHEMBL31367742 | 0.84 | ALDH1A1 (0.34) | ALDH1A1HSD17B10TDP1CA1CA9 | |
| SCHEMBL27369528 | 0.82 | CES2 (0.43) | ALDH1A1HSD17B10TDP1SOS1CES2 | |
| SCHEMBL15576946 | 0.80 | ALDH1A1 (0.32) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL732747 | 0.80 | CES2 (0.38) | ALDH1A1HSD17B10TDP1CES2CA1 | |
| SCHEMBL24572331 | 0.79 | ALDH1A1 (0.31) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL2009173 | 0.79 | HCAR1 (0.52) | ALDH1A1HSD17B10TDP1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119320374-B | Method for synthesizing 3-sulfonyl substituted chromone derivative by photocatalysis | JIANG University OF TECHNOLOGY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-122079918-A | Isoxazole biphenyl compounds with CBP BRD and BRD4 BD2 inhibitory activity, and preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026107425-A1 | 5-(PYRIDIN-4-YL)-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20260014119-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260001864-A1 | COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION | NANJING SHUOHUI PHARMATECHNOLOGY CO., LTD (CN) | 2026-01-01 | — | — | US | disclosed |
| EP-4596534-A1 | NONCOVALENT SMALL-MOLECULE INHIBITORS OF THE KEAP1-NRF2 INTERACTION | University of Copenhagen (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4554934-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-15 | — | — | US | disclosed |
| US-20040157823-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2004-08-12 | — | — | US | disclosed |
| US-20040142954-A1 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2004-07-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| US-6734176-B2 | ARE CB1-RECEPTOR ANTAGONISTS AND ARE USEFUL IN THE TREATMENT AND PREVENTION OF DISORDERS AFFECTING THE CENTRAL NERVOUS, IMMUNE, CARDIOVASCULAR OR ENDOCRINE, RESPIRATORY, GASTROINTESTINAL AND REPRODUCTIVE SYSTEMS; DRUG ABUSE | AVENTIS PHARMA S.A. (FR) | 2004-05-11 | — | — | US | disclosed |
| WO-2003099231-A2 | HETEROARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | COLLONGES FRANCOIS (FR) | 2003-10-30 | — | — | US | disclosed |
| US-20030119810-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2003-06-26 | — | — | US | disclosed |
| US-6566356-B2 | 3-amido or 3-sulfonylamino azetidine compounds and their preparation; high affinity for cannabinoid receptor CB1 type, useful in treating central nervous system, immune, gastrointestinal or cardiovascular disorders, drug abuse | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | disclosed |
| US-6509499-B1 | Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-01-21 | — | — | US | disclosed |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014119-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBP, EBPL, ELP1 | ALDH1A1 3608/4885HSD17B10 1820/4885TDP1 2035/4885 |
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | ALDH1A1 4260/4885HSD17B10 733/4885TDP1 3878/4885 |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | ALDH1A1 2583/4885HSD17B10 2868/4885TDP1 1505/4885 |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | HRH2, ALK, HRH1 | ALDH1A1 1211/4885HSD17B10 1357/4885TDP1 2999/4885 |
| US-20040157823-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | ALK, HRH2, HRH1 | ALDH1A1 1049/4885HSD17B10 1217/4885TDP1 2031/4885 |
| US-20030119810-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | ALK, HRH2, HRH1 | ALDH1A1 1049/4885HSD17B10 1217/4885TDP1 2031/4885 |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | ALDH1A1 3076/4885HSD17B10 2354/4885TDP1 1722/4885 |
| US-20260001864-A1 | COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION | SLC10A2, SLC6A11, ABCB11 | ALDH1A1 1595/4885HSD17B10 2271/4885TDP1 4802/4885 |
| US-20040142954-A1 | Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | VCAM1, ITGB4, ITGA4 | ALDH1A1 389/4885HSD17B10 1174/4885TDP1 4228/4885 |
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | ALDH1A1 3089/4885HSD17B10 2379/4885TDP1 1753/4885 |
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | AKR1B1, ALDOA, AKR1C1 | ALDH1A1 48/4885HSD17B10 161/4885TDP1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.